title: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
abstract: OBJECTIVE
  We report the effects of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of advanced/recurrent epithelial ovarian cancer (EOC) on survival, morbidity and mortality.
  
  
  METHODS
  Forty EOC patients were studied. Median age was 52.5 years (range: 30-68) and median follow-up 26.1 months (range: 0.3-117.6). Most patients presented advanced disease (stage III/IV). Previous systemic chemotherapy included cisplatin-based, taxol-based or taxol/platinum containing regimens.
  
  
  RESULTS
  After the CRS, 33 patients presented no macroscopic residual disease. Five-year overall survival was 15%; the mean overall and progression-free survivals were 41.4 and 23.9 months, respectively. The morbidity, toxicity and mortality rates were 5%, 15% and 0%, respectively.
  
  
  CONCLUSIONS
  Our results suggest that CRS + IPHP merits further evaluation by a formal prospective trial.
authors.affiliation: Department of Surgery-Gynaecology Unit, National Cancer Institute of Milan, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Raspagliesi
authors.forename: S
authors.initials: S
authors.lastname: Kusamura
authors.forename: J C
authors.initials: JC
authors.lastname: Campos Torres
authors.forename: G A
authors.initials: GA
authors.lastname: de Souza
authors.forename: A
authors.initials: A
authors.lastname: Ditto
authors.forename: F
authors.initials: F
authors.lastname: Zanaboni
authors.forename: R
authors.initials: R
authors.lastname: Younan
authors.forename: D
authors.initials: D
authors.lastname: Baratti
authors.forename: L
authors.initials: L
authors.lastname: Mariani
authors.forename: B
authors.initials: B
authors.lastname: Laterza
authors.forename: M
authors.initials: M
authors.lastname: Deraco
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin